153 related articles for article (PubMed ID: 24494606)
1. The role of dose reduction with NSAID use.
Matthews ML
Am J Manag Care; 2013 Nov; 19(14 Suppl):s273-7. PubMed ID: 24494606
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the impact of NSAID-associated adverse events.
Fine M
Am J Manag Care; 2013 Nov; 19(14 Suppl):s267-72. PubMed ID: 24494609
[TBL] [Abstract][Full Text] [Related]
3. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
4. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
5. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
[TBL] [Abstract][Full Text] [Related]
6. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians.
Scheiman JM
J Clin Gastroenterol; 2016 Jan; 50(1):5-10. PubMed ID: 26524151
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
8. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews.
Odom DM; Mladsi DM; Saag KG; Sherif BN; Miles L; Ronquest N; Wang J
Clin Ther; 2014 Jun; 36(6):906-17. PubMed ID: 24863260
[TBL] [Abstract][Full Text] [Related]
9. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
Farkouh ME; Greenberg BP
Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
[TBL] [Abstract][Full Text] [Related]
10. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
11. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
[TBL] [Abstract][Full Text] [Related]
13. Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness.
Targownik LE; Thomson PA
Can Fam Physician; 2006 Sep; 52(9):1100-5. PubMed ID: 17279220
[TBL] [Abstract][Full Text] [Related]
14. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
15. NSAIDs-induced gastrointestinal damage. Review.
Arroyo M; Lanas A
Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
Borer JS; Simon LS
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
[TBL] [Abstract][Full Text] [Related]
17. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
Scheiman JM; Fendrick AM
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
[TBL] [Abstract][Full Text] [Related]
18. [Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs].
Sostres C; Lanas Á
Med Clin (Barc); 2016 Mar; 146(6):267-72. PubMed ID: 26724872
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging treatments for mild/moderate acute ambulatory pain.
Weaver AL
Am J Ther; 2008; 15 Suppl 10():S12-6. PubMed ID: 19127123
[TBL] [Abstract][Full Text] [Related]
20. Evolution to low-dose NSAID therapy.
Pergolizzi JV; Raffa RB; Nalamachu S; Taylor R
Pain Manag; 2016 Apr; 6(2):175-89. PubMed ID: 26980438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
